Literature DB >> 15211067

Severe cerebral amyloid angiopathy characterizes an underestimated variant of vascular dementia.

Mattias Haglund1, Martin Sjöbeck, Elisabet Englund.   

Abstract

Cerebral amyloid angiopathy (CAA) is a frequent finding on neuropathological examination of patients with Alzheimer's disease (AD). A recent study from our laboratory showed that CAA also frequently occurred in vascular dementia with additional mild Alzheimer encephalopathy (VaD-ae, i.e. Alzheimer pathology that does not fulfill criteria for AD). Because CAA is associated with cerebral hemorrhages and infarctions, it is of significant interest to confirm or dismiss the hypothesis that CAA contributes clinically in the many patients that present with VaD-ae. Therefore, we examined entire temporal lobes of 11 VaD-ae cases and 11 age-matched AD cases with Abeta immunohistochemistry. Six of 11 VaD-ae cases had severe CAA, more extensive than in any AD case. There was a trend toward more cortical infarctions in this group, indicating that CAA in VaD may be of clinical importance and an underestimated cause of dementia. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15211067     DOI: 10.1159/000079192

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  15 in total

1.  Inflammation complicates an 'age-related' cerebral microangiopathy.

Authors:  Harry V Vinters
Journal:  Can J Neurol Sci       Date:  2011-07       Impact factor: 2.104

2.  The relationship between cerebral amyloid angiopathy and cortical microinfarcts in brain ageing and Alzheimer's disease.

Authors:  E Kövari; F R Herrmann; P R Hof; C Bouras
Journal:  Neuropathol Appl Neurobiol       Date:  2013-08       Impact factor: 8.090

3.  [Sporadic cerebral amyloid angiopathy with ischemic leukoencephalopathy and microbleeds. Cause for a rapidly progressive dementia syndrome].

Authors:  J Katchanov; G Bohner; M Könneker; U Kopp; K Izadpanah; E Larmann; R Klingebiel; F van Landeghem; F Masuhr; R Zschenderlein
Journal:  Nervenarzt       Date:  2005-10       Impact factor: 1.214

4.  "Cerebral Small Vessel Disease in subclinical and clinical stages, role of inflammation for risk prediction and potential treatment targets, and management strategies".

Authors:  C Frances Fan; José R Romero
Journal:  Intern Med Rev (Wash D C)       Date:  2016-12

5.  Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia.

Authors:  Wolff Kirsch; Grant McAuley; Barbara Holshouser; Floyd Petersen; Muhammad Ayaz; Harry V Vinters; Cindy Dickson; E Mark Haacke; William Britt; James Larseng; Ivan Kim; Claudius Mueller; Matthew Schrag; Daniel Kido
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

6.  Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.

Authors:  Keith A Johnson; Satoshi Minoshima; Nicolaas I Bohnen; Kevin J Donohoe; Norman L Foster; Peter Herscovitch; Jason H Karlawish; Christopher C Rowe; Maria C Carrillo; Dean M Hartley; Saima Hedrick; Virginia Pappas; William H Thies
Journal:  Alzheimers Dement       Date:  2013-01       Impact factor: 21.566

7.  Cerebral microvascular rather than parenchymal amyloid-β protein pathology promotes early cognitive impairment in transgenic mice.

Authors:  Wenjin Xu; Feng Xu; Maria E Anderson; AnnMarie E Kotarba; Judianne Davis; John K Robinson; William E Van Nostrand
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

8.  Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy.

Authors:  Virawudh Soontornniyomkij; Matthew D Lynch; Sherin Mermash; Justine Pomakian; Haleh Badkoobehi; Ryan Clare; Harry V Vinters
Journal:  Brain Pathol       Date:  2009-07-16       Impact factor: 6.508

Review 9.  Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review.

Authors:  Hannah A D Keage; Roxanna O Carare; Robert P Friedland; Paul G Ince; Seth Love; James A Nicoll; Stephen B Wharton; Roy O Weller; Carol Brayne
Journal:  BMC Neurol       Date:  2009-01-13       Impact factor: 2.474

Review 10.  Outcome markers for clinical trials in cerebral amyloid angiopathy.

Authors:  Steven M Greenberg; Rustam Al-Shahi Salman; Geert Jan Biessels; Mark van Buchem; Charlotte Cordonnier; Jin-Moo Lee; Joan Montaner; Julie A Schneider; Eric E Smith; Meike Vernooij; David J Werring
Journal:  Lancet Neurol       Date:  2014-02-27       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.